Lebensqualität und Lebenserwartung am malignen Lymphom erkrankter Hunde unter Chemotherapie

Zusammenfassung

Gegenstand und Ziel: Der Erfolg palliativer Chemotherapien bei Hunden mit malignem Lymphom wurde insbesondere in Bezug auf die Lebensqualität der Tiere evaluiert. Zudem wurden Faktoren erfasst, die für die Besitzer bei der Einschätzung der Lebensqualität ihrer Tiere sowie für ihre Gesamtbewertung der Therapie eine entscheidende Rolle spielten. Material und Methoden: Die retrospektive Befragung mittels eines Fragebogens bezüglich Krankheitsverlauf und Therapie ihrer Tiere richtete sich an 207 Hundebesitzer, deren Hunde in den letzten 13 Jahren zur Chemotherapie in der Medizinischen Kleintierklinik der LudwigMaximilians-Universität München vorgestellt worden waren. Ergebnisse: 123 Besitzer (59,4%) beantworteten den Fragebogen. Bei 64 Hunden (53,3%) ließ sich aus Sicht der Besitzer mit der Chemotherapie eine Verbesserung der Lebensqualität erreichen. Nur bei 24 Hunden (20,0%) kam es zu einer Verschlechterung der Lebensqualität, die in direktem Zusammenhang mit dem Remissionsstatus und Nebenwirkungen der Chemotherapie stand. Die Remissionsrate der Hunde lag bei 83,7%. Schlussfolgerung: Der Großteil der Besitzer (65,0%) war zufrieden mit der Chemotherapie. 90 Besitzer (73,2%) würden sich erneut für eine solche Behandlung entscheiden, wobei insbesondere die Lebensverlängerung ein wichtiges Entscheidungskriterium darstellte. Klinische Relevanz: Bei Tumorpatienten, die eine palliative Chemotherapie erhalten, muss die Lebensqualität konstant überwacht werden. Nur so kann sie bei der Auswahl geeigneter Chemotherapie-Protokolle helfen und zusätzlich Besitzer und Tierarzt die Entscheidung für den weiteren Verlauf der Therapie erleichtern.

Summary

Objective: The outcome of palliative chemotherapy in dogs with lymphoma was evaluated. Special emphasis was placed on the quality of life during chemotherapy. In addition, factors which were important for the owners in estimating their dogs’ quality of life and for the assessment of therapy were recorded. Material and methods: In a retrospective study the owners of 207 dogs that had undergone chemotherapy at the Clinic of Small Animal Medicine, University of Munich during the previous 13 years, were asked about their dogs’ course of disease and therapy by using a specially designed questionnaire. Results: A total of 123 owners (59.4%) responded to the questionnaire. Quality of life improved in 64 dogs (53.3%) during chemotherapy. In only 24 dogs (20.0%) was a decline in the quality of life recorded, that directly correlated with remission status and side effects.The overall remission rate in dogs undergoing chemotherapy was 83.7%. Conclusion: Despite treatment complications, the majority of the owners (65.0%) were satisfied by the chemotherapy of their dogs. Ninety owners (73.2%) would have treated their animal with chemotherapy again; for this decision prolonged survival was an important factor. Clinical relevance: In dogs with cancer the quality of life needs to be monitored constantly during palliative chemotherapy. This assessment helps to choose the appropriate chemotherapy protocol and facilitates the decision on further treatment options by the owner and the veterinarian.

Schlüsselwörter

Hund - malignes Lymphom - palliative Chemotherapie - Fragebogen - Besitzer

Key words

Dog - malignant lymphoma - palliative chemotherapy - questionnaire - owner

• Literatur

• 1 Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997; 50: 1129-1136.
• 2 Bowles DB, Robson MC, Galloway PE, Walker L. Owner’s perception of carboplatin in conjunction with other palliative treatments for cancer therapy. J Small Anim Pract 2010; 51: 104-112.
• 3 Bronden LB, Rutteman GR, Flagstad A, Teske E. Study of dog and cat owners’ perceptions of medical treatment for cancer. Vet Rec 2003; 125: 77-80.
• 4 Couto CG, Cullen J, Pedroia V, Turrel JM. Central nervous system lymphosarcoma in the dog. J Am Vet Med Assoc 1984; 184: 809-813.
• 5 Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wenzt R, Kwan I, Cooper R. Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev. 2007 18. MR00008.
• 6 Ettinger SN. Principles of treatment for canine lymphoma. Clin Tech Small Anim Pract 2003; 18: 92-97.
• 7 Fontaine J, Bovens C, Bettenay S, Mueller RS. Canine cutaneous epitheliotropic T-cell-lymphoma: a review. Vet Comp Oncol 2009; 07: 1-14.
• 8 Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 2001; 40: 175-184.
• 9 Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993; 07: 289-295.
• 10 Lee JJ, Hughes CS, Fine RL, Page RL. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892-1898.
• 11 Mellanby RJ, Herrtage ME, Dobson JM. Treatment of canine Lymphoma by veterinarians in first opinion practice in England. J Small Anim Pract 2002; 43: 198-202.
• 12 Mellanby RJ, Herrtage ME, Dobson JM. Owners’ assessments of their dog’s quality of life during palliative chemotherapy for lymphoma. J Small Anim Pract 2003; 44: 100-103.
• 13 Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual Life Res 1992; 01: 211-218.
• 14 Priebe S, Gruyters T. The role of the helping alliance in psychiatric community care. A prospective study. J Nerv Men Dis 1993; 181: 552-557.
• 15 Rassnick KM, Moore AS, Collister KE, Northrup NC, Kristal O, Chretin JD, Bailey DB. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. J Vet Intern Med 2009; 23: 317-322.
• 16 Ruppaner R. Measurement of disease in animal populations based on interviews. J Am Vet Med Assoc 1972; 161: 1033-1038.
• 17 Simon D, Nolte I, Eberle N, Abbrederis N, Killich M, Hirschberger J. Treatment of dogs with Lymphoma Using a 12-Week, Maintenance-Free Combination Chemotherapy Protocol. J Vet Intern Med 2006; 20: 948-954.
• 18 Tzannes S, Hammond MF, Murphy S, Sparkes A, Blackwood L. Owners ‘perception of their cats’ quality of life during COP chemotherapy for lymphoma. J Feline Med Surg 2008; 10: 73-81.
• 19 Valerius K, Ogilvie G, Mallinckrodt C, Getzy D. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987–1995). J Am Vet Med Assoc 1997; 210: 512-516.
• 20 Von Wethern CJ, Horst C, Schwarz G. Zur Gliedmaßenamputation bei Hund und Katze: Eine Besitzerbefragung. Kleintierprax 1999; 44: 169-176.
• 21 Walker A, Restuccia J. Obtaining information on patient satisfaction with hospital care: mail versus telephone. Health Serv Res 1984; 19: 291-306.
• 22 Yazbek KV, Fantoni DT. Validity of a health-related quality-of-life scale for dogs with signs of pain secondary to cancer. J Am Vet Med Assoc 2005; 226: 1354-1358.
• 23 Yeates J, Main D. Assessment of companion animal quality of life in veterinary practice and research. J Small Anim Pract 2009; 50: 274-281.
• 24 Zenker I, Meichner K, Steinle K, Kessler M, Hirschberger J. A 13-week Dose Intensifying Simultaneous Combination Chemotherapy (DISC) Protocol for Malignant Lymphoma in Dogs: 21 Cases. Vet Rec 2010; 167 (19) 744-748.